Detection of the selective androgen receptor modulator S-4 (Andarine) in a doping control sample

Drug Testing and Analysis

Volumn 5, Issue 5, 2013, Pages 377-379

  Starcevic, Borislav ^a   Ahrens, Brian D ^a   Butch, Anthony W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTORS; CONTROL SAMPLES; DOPING CONTROL;

SAMPLING;

ANDROSTANEDIOL; ANDROSTERONE; DRUG METABOLITE; EPITESTOSTERONE; ETIOCHOLANOLONE; MEGESTROL ACETATE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TESTOSTERONE;

ATHLETE; DOPING; DRUG SCREENING; GAS CHROMATOGRAPHY; HORMONE DETERMINATION; HUMAN; HYDROLYSIS; LETTER; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; PRIORITY JOURNAL; STEROID URINE LEVEL; TANDEM MASS SPECTROMETRY; URINALYSIS;

EID: 84878258275     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1466     Document Type: Letter

References (20)

1. R. Narayanan, M. L. Mohler, C. E. Bohl, D. D. Miller, J. T. Dalton. Selective androgen receptor modulators in preclinical and clinical development. Nucl. Recept. Signaling 2008, 6, e010.
2. S. Bhasin, R. Jasuja. Selective androgen receptor modulators (SARMs) as function promoting therapies. Curr. Opin. Nutr. Metab. Care 2009, 12, 232.
3. B. Haendler, A. Cleve. Recent developments in antiandrogens and selective androgen receptor modulators. Mol. Cell. Endocrinol. 2012, 352, 79.
4. W. Gao, J. D. Kearbey, V. A. Nair, K. Chung, A. F. Parlow, D. D. Miller, et al. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5α-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology 2004, 145, 5420.
5. W. Gao, P. J. Reiser, C. C. Coss, M. A. Phelps, J. D. Kearbey, D. D. Miller, et al. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 2005, 146, 4887.
6. S. Bhasin, O. M. Calof, T. W. Storer, M. L. Lee, N. A. Mazer, R. Jasuja, et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat. Clin. Pract. Endocrinol. Metab. 2006, 2, 146.
7. M. Thevis, H. Geyer, M. Kamber, W. Schänzer. Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product. Drug Test. Anal. 2009, 1, 387.
8. M. Thevis, A. Thomas, I. Möller, H. Geyer, J. T. Dalton, W. Schänzer. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator S-22 to identify potential targets for routine doping controls. Rapid Commun. Mass Spectrom. 2011, 25, 2187.
9. J. T. Dalton, K. G. Barnette, C. E. Bohl, M. L. Hancock, D. Rodriguez, S. T. Dodson, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2011, 2, 153.
10. Enobosarm (Ostarine®; GTx-024). Available at: http://www.gtxinc.com/Pipeline/OstarineMK2866.aspx?Sid=4 [22 January 2013].
11. M. Thevis, W. Schänzer. Mass spectrometry of selective androgen receptor modulators. J. Mass Spectrom. 2008, 43, 865.
12. T. Kuuranne, A. Leinonen, W. Schänzer, M. Kamber, R. Kostiainen, M. Thevis. Aryl-priopionamide-derived selective androgen receptor modulators: liquid chromatography-tandem mass spectrometry characterization of the in vitro synthesized metabolites for doping. Drug Metab. Dispos. 2008, 36, 571.
13. S. Guddat, E. Solymos, A. Orlovius, A. Thomas, G. Sigmund, H. Geyer, et al. High-throughput screening for various classes of doping agents using a new 'dilute-and-shoot' liquid chromatography-tandem mass spectrometry multi-target approach. Drug Test. Anal. 2011, 3, 836.
14. E. Grata, L. Perrenoud, M. Saugy, N. Baume, SARM-S4 and metabolites detection in sports drug testing: a case report. Forensic Sci. Int. 2011, 213, 104.
15. A. Thomas, H. Geyer, W. Schänzer, C. Crone, M. Kellmann, T. Moehring, M Thevis. Sensitive determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop quadrupole/orbitrap mass spectrometer. Anal. Bioanal. Chem. 2012, 403, 1279.
16. M. Thevis, M. Kohler, A. Thomas, N. Schlörer, W. Schänzer. Doping control analysis of tricyclic tetrahydroquinoline-derived selective androgen receptor modulators using liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2008, 22, 2471.
17. B. D. Ahrens, B. Starcevic, A. W. Butch. Detection of prohibited substances by liquid chromatography tandem mass spectrometry for sports doping control, in Drug Analysis: Methods and Protocols, (Eds: L. J. Langman, C. L. H. Snozek ). Humana Press: Totowa, 2012, pp. 115-128.
18. A. Breidbach, D. H. Catlin. RSR13, a potential athletic performance enhancement agent: detection in urine by gas chromatography/mass spectrometry. Rapid Commun. Mass Spectrom. 2001, 15, 2379.
19. M. Thevis, A. Thomas, G. Fußhöller, S. Beuck, H. Geyer, W. Schänzer. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator andarine (S-4) for routine doping control purposes. Rapid Commun. Mass Spectrom. 2010, 24, 2245.
20. D. Bogle. JAAA awaits result of Wilkins drug hearing. Jamaica Observer 14 July 2010. Available at: http://www.jamaicaobserver.com/sports/JAAA-awaits-result-of-Wilkins-drugs-hearing_7796590 [19 December 2012].